About
XPAMAC develops next-generation mammalian cell lines based on a proprietary Mammalian Elongated Chromosome (MEC) platform to enable efficient, stable, and scalable production of therapeutic proteins for biopharma and CDMO partners.
Explore XPAMAC's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.